Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, reports small decreases in PFS for obese patients treated with CDK4/6 inhibitors and endocrine therapy in the MONARCH 1 (NCT02102490) and MONARCH 2 (NCT02107703) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.